Small Cell Lung Cancer Treated in Second Line and Later

Joshua Sabari, MD, discusses lurbinectedin maintenance candidacy, supportive care strategies, and the critical need for biomarkers in ES-SCLC.

Explore real-world extensive-stage SCLC care, with frontline chemoimmunotherapy, steep therapy attrition, NCCN updates, and evidence favoring 4 chemotherapy cycles.

IMforte shows lurbinectedin plus atezolizumab maintenance extends PFS and OS in extensive-stage SCLC, with manageable cytopenias and key patient-selection guidance.

Explore frontline chemo‑immunotherapy choices in extensive-stage SCLC, NCCN updates, and why patient drop-off shapes second- and third-line care.

During a live event, Joshua K. Sabari, MD, discussed subgroup analyses and safety outcomes of the IMforte trial in extensive-stage small cell lung cancer.

During a live event, Joshua K. Sabari, MD, discussed outcomes of the phase 3 IMforte trial in extensive-stage small cell lung cancer.

During a live event, Wade T. Iams, MD, MSCI, discussed potential ways to determine which patients benefit most from additional therapy for extensive-stage small cell lung cancer.

During a live event, Wade T. Iams, MD, MSCI, examined outcomes of the phase 3 IMforte trial in extensive-stage small cell lung cancer.